Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
$9.06
-$0.70(-11.71%)
At close: 4:00 PM EST
$9.06
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$2.83 - $11.50
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.24M
Market Cap
$947.96M
Enterprise Value$712.19M
Total Cash (Recent Filing)$239.95M
Total Debt (Recent Filing)$31.87M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding104,631,830
10 Day Avg. Volume1,243,357
30 Day Avg. Volume1,242,989
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-8.94
Enterprise Value/Market Cap0.75
Enterprise Value/Revenue10.23
Enterprise Value/Gross Profit45.14
Enterprise Value/Ebitda-10.02
Forecast
1Y Price Target
$12.00Price Target Upside32.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.97
Revenue Forecast (FY)$81.68M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And Commercialization FundingA large cash raise from an ATM facility materially de-risked the balance sheet and enables increased marketing and sales investment to support a more aggressive commercial launch.
Commercial Traction And Test Volume GrowthClinical test volumes and annual test counts have risen sharply and commercial partner Tempus is effectively selling the test, signaling accelerating market adoption for the NeXT Personal MRD offering.
Reimbursement ExpansionMedicare coverage for breast and lung cancer tests and expanded coverage for the NeXT Personal test reduces commercial risk and supports broader reimbursement prospects that can drive greater clinical adoption.
Bears Say
Below-consensus Revenue GuidanceRevenue guidance for 2026 was provided below analyst consensus, introducing downside risk to earnings expectations and valuation assumptions.
Competitive Pressure And Near-term UncertaintyAnalyst lowered revenue forecasts and signaled caution due to competitive pressure from Natera and pending full reported results, increasing uncertainty around near-term revenue momentum.
Profitability Pressure From Reimbursement MixNear-term gross margins and cash burn are expected to deteriorate as low-reimbursement MRD volumes ramp, creating pressure on profitability until reimbursement expands.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $11.50 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $947.96M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is May 06, 2026 which is in 64 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Feb 26, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.028.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.27.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 104,631,830 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 0.332%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (32.45% Upside)
$12.00 (32.45% Upside)
Blogger Sentiment
Bearish
PSNL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 58.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 13.5%
Last 30 Days ▲ 13.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.84%
12-Months-Change
Fundamentals
Return on Equity
-35.02%
Trailing 12-Months
Asset Growth
23.64%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial and clinical momentum (massive Clinical test growth, nearly 240% MRD biopharma revenue increase, two Medicare coverage wins, deepening evidence base and product innovation) alongside an intentional, transitional financial profile (legacy revenue wind-downs, margin compression from unreimbursed volume, higher operating losses and increased cash burn as the company scales). Management presented a clear strategy to trade near-term margins and higher cash usage for accelerated market share and reimbursement conversion, supported by a strong cash position and multiple validation points. Upside depends on further reimbursement rollouts (e.g., IO) and steady biopharma demand/timing.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$12.00
▲(32.45% Upside)
Technical Analysis
Ownership Overview
0.68% Insiders
10.62% Mutual Funds
15.29% Other Institutional Investors
56.87% Public Companies and
Individual Investors